On the public citation graph

Pharmacoepidemiology Study of Antibody-Drug Conjugate-Associated Interstitial Lung Disease

0 signed · 30 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1002/cac2.12387openalex-extracted
Resistance to antibody‐drug conjugates in breast cancer: mechanisms and solutions
inferredcites →https://doi.org/10.1007/s40265-022-01736-wopenalex-extracted
Trastuzumab Deruxtecan-Induced Interstitial Lung Disease/Pneumonitis in ERBB2-Positive Advanced Solid Malignancies: A Systematic Review
inferredcites →https://doi.org/10.1016/j.annonc.2023.09.3114openalex-extracted
The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma
inferredcites →https://doi.org/10.1016/j.annonc.2023.12.001openalex-extracted
Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01)
inferredcites →https://doi.org/10.1016/j.breast.2021.11.016openalex-extracted
The first reported case of trastuzumab induced interstitial lung disease associated with anti-neutrophil cytoplasmic antibody vasculitis – A case report and a prospective cohort study on the usefulness of neutrophil derived biomarkers in monitoring vasculitis disease activity during follow-up
inferredcites →https://doi.org/10.1016/j.clbc.2023.09.005openalex-extracted
Efficacy and Safety of Trastuzumab Deruxtecan in Breast Cancer: A Systematic Review and Meta-Analysis
inferredcites →https://doi.org/10.1016/j.drudis.2008.12.012openalex-extracted
Decision support methods for the detection of adverse events in post-marketing data
inferredcites →https://doi.org/10.1016/j.drup.2014.11.001openalex-extracted
Antibody-targeted drugs and drug resistance—Challenges and solutions
inferredcites →https://doi.org/10.1016/j.eclinm.2023.101967openalex-extracted
Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database
inferredcites →https://doi.org/10.1016/j.ejca.2018.12.022openalex-extracted
Safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive advanced breast cancer: Primary results from the KAMILLA study cohort 1
inferredcites →https://doi.org/10.1016/j.esmoop.2022.100404openalex-extracted
Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment
inferredcites →https://doi.org/10.1016/j.pharmthera.2019.04.008openalex-extracted
Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates
inferredcites →https://doi.org/10.1016/s1470-2045(14)70178-0openalex-extracted
Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial
inferredcites →https://doi.org/10.1016/s1470-2045(19)30088-9openalex-extracted
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study
inferredcites →https://doi.org/10.1056/nejmoa1814017openalex-extracted
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
inferredcites →https://doi.org/10.1056/nejmoa1914510openalex-extracted
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
inferredcites →https://doi.org/10.1056/nejmoa2028485openalex-extracted
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
inferredcites →https://doi.org/10.1080/14740338.2023.2204228openalex-extracted
High risks adverse events associated with trastuzumab emtansine and trastuzumab deruxtecan for the treatment of HER2-positive/mutated malignancies: a pharmacovigilance study based on the FAERS database
inferredcites →https://doi.org/10.1159/000511049openalex-extracted
Management of Chemotherapy-Induced Nausea and Vomiting with Trastuzumab Deruxtecan: A Case Series
inferredcites →https://doi.org/10.1177/17534666221117002openalex-extracted
Immunomodulatory treatment of interstitial lung disease
inferredcites →https://doi.org/10.1182/blood.2020008404openalex-extracted
ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient–derived xenograft mouse models
inferredcites →https://doi.org/10.1183/13993003.02776-2021openalex-extracted
Drug-induced interstitial lung disease
inferredcites →https://doi.org/10.1186/1745-6215-13-138openalex-extracted
Drug safety assessment in clinical trials: methodological challenges and opportunities
inferredcites →https://doi.org/10.1200/jco.19.02318openalex-extracted
Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study
inferredcites →https://doi.org/10.1248/cpb.c18-00744openalex-extracted
The Latest Research and Development into the Antibody–Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy
inferredcites →https://doi.org/10.3322/caac.21492openalex-extracted
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
inferredcites →https://doi.org/10.3322/caac.21834openalex-extracted
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
inferredcites →https://doi.org/10.3389/fonc.2023.1121708openalex-extracted
Genomic landscape and efficacy of HER2-targeted therapy in patients with HER2-mutant non-small cell lung cancer
inferredcites →https://doi.org/10.3390/antib10040042openalex-extracted
Introduction to Antibody-Drug Conjugates
inferredcites →https://doi.org/10.7150/ijms.6048openalex-extracted
Data Mining of the Public Version of the FDA Adverse Event Reporting System
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.